Phibro Animal Health faces FDA actions to revoke Mecadox approval; $20M sales at risk

PHIBRO ANIMAL HEALTH CORP

FDA issued final order revoking approved method for detecting carbadox residues in swine.
FDA proposed to withdraw all new animal drug applications for Mecadox in swine feed; Phibro may request hearing.
Mecadox sales for fiscal year ended June 30, 2023 were approximately $20 million.
Phibro states it is extremely disappointed, believes in safety, and will defend Mecadox's continued use.
Company notes 50+ year history of safe use and intends to take appropriate action against FDA's steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.